{"schema_version":"secwatch.filing_event.v1","accession":"0001528287-23-000033","form_type":"8-K","ticker":"NPCE","cik":"0001528287","company_name":"NeuroPace Inc","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.207733+00:00","generated_at":"2026-06-12T01:45:01.993863+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NeuroPace Q2 revenue $16.5M (+62% YoY); raises FY 2023 guidance to $59-61M","bullets":["Q2 revenue $16.5M, up 62% YoY and 14% QoQ; net loss narrowed to $9.1M from $12.7M YoY.","Full-year 2023 revenue guidance raised to $59-61M (30-34% growth), from prior $52-54M.","Cash burn reduced to $4M in Q2 from $9.8M in Q1; cash and investments $63.6M at June 30.","NAUTILUS trial enrollment on track; full enrollment expected Q1 2024 for generalized epilepsy.","Gross margin 72.5%; operating expenses flat YoY; DIXI product distribution contributed to revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001528287-23-000033","json":"https://secwatch.observer/filing/0001528287-23-000033.json","markdown":"https://secwatch.observer/filing/0001528287-23-000033.md","text":"https://secwatch.observer/filing/0001528287-23-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000033/0001528287-23-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000033/npce-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T01:45:01.993863+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f0c3bb57a2515a5a47236760a2a468f0b367594","claim":"NeuroPace Inc reported full year 2023 results: revenue $59 million to $61 million. Guidance raised.","evidence_excerpt":"Increased total revenue guidance to range between $59 million and $61 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000033/0001528287-23-000033-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year 2023"},{"label":"Revenue","value":"$59 million to $61 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"b769217bac2f8f4de409245834723e2eae2864c0","claim":"NeuroPace Inc reported the second quarter ended June 30, 2023 results: revenue $16.5 million, net income $9.1 million.","evidence_excerpt":"Total revenue was $16.5 million in the second quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828723000033/0001528287-23-000033-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Revenue","value":"$16.5 million"},{"label":"Net income","value":"$9.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}